This paper reviews state-of-art statistical designs for dose-escalation procedures in first-into-man studies. The main focus will be on studies in oncology, as most statistical procedures for phase I trials have been proposed in this context. Extensions to situations such as the observation of bivariate outcomes and healthy volunteer studies are also discussed. The number of dose levels and cohort sizes used in early phase trials are considered. Finally, this paper raises some practical issues for dose-escalation procedures
BACKGROUND: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
An efficient phase I trial is a crucial step in developing a new drug in a safe and timely manner. T...
Clinical trials are experiments tested on human to compare the effect of certain intervention. In ea...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
This chapter describes the main rule-based and model-based approaches for conducting phase I dose-es...
In a dose-escalation trial for a new drug, each successive dose is tested on a new cohort of volunte...
In modern drug development, there has been an increasing interest in adaptive clinical trials—resear...
International audienceBackground Combining several anticancer agents can increase the overall antitu...
International audienceBackground Combining several anticancer agents can increase the overall antitu...
A rapidly increasing number of Phase I dose-finding studies, and in partic-ular those based on the s...
Adaptive clinical trials are becoming increasingly popular research designs for clinical investigati...
Statistical simulations have consistently demonstrated that new dose-escalation designs such as acce...
Dose escalation trials for identifying the maximum tolerable dose (MTD) is commonly considered in ph...
The primary goal of phase I dose-finding trials has been historically to understand the safety profi...
BACKGROUND: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
An efficient phase I trial is a crucial step in developing a new drug in a safe and timely manner. T...
Clinical trials are experiments tested on human to compare the effect of certain intervention. In ea...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
This chapter describes the main rule-based and model-based approaches for conducting phase I dose-es...
In a dose-escalation trial for a new drug, each successive dose is tested on a new cohort of volunte...
In modern drug development, there has been an increasing interest in adaptive clinical trials—resear...
International audienceBackground Combining several anticancer agents can increase the overall antitu...
International audienceBackground Combining several anticancer agents can increase the overall antitu...
A rapidly increasing number of Phase I dose-finding studies, and in partic-ular those based on the s...
Adaptive clinical trials are becoming increasingly popular research designs for clinical investigati...
Statistical simulations have consistently demonstrated that new dose-escalation designs such as acce...
Dose escalation trials for identifying the maximum tolerable dose (MTD) is commonly considered in ph...
The primary goal of phase I dose-finding trials has been historically to understand the safety profi...
BACKGROUND: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
An efficient phase I trial is a crucial step in developing a new drug in a safe and timely manner. T...
Clinical trials are experiments tested on human to compare the effect of certain intervention. In ea...